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Purpose
The purpose of this study was to develop nomograms for predicting the probability of overall
survival (OS) and progression-free survival (PFS) in locally advanced cervical cancer  treated
with neoadjuvant chemotherapy  and radical surgery.
Materials and Methods
Nomograms to predict the 5-year OS rates and the 2-year PFS rates were constructed. Cali-
bration plots were constructed, and concordance indices were calculated. Evaluated vari-
ables were body mass index, age, tumor size, tumor histology, grading, lymphovascular space
invasion, positive parametria, and positive lymph nodes. 
Results
In total 245 patients with locally advanced cervical cancer who underwent neoadjuvant
chemotherapy and radical surgery were included for the construction of the nomogram. The
5-year OS and PFS were 72.6% and 66%, respectively. Tumor size, grading, and parametria
status affected the rate of OS, whereas tumor size and positive parametria were the main
independent PFS prognostic factors.  
Conclusion
We constructed a nomogram based on clinicopathological features in order to predict 
2-year PFS and 5-year OS in locally advanced cervical cancer primarily treated with neoad-
juvant chemotherapy followed by radical surgery. This tool might be particularly helpful for
assisting in the follow-up of cervical cancer patients who have not undergone concurrent
chemoradiotherapy. 
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Introduction
Cervical cancer is the third most commonly diagnosed can-
cer and the fourth leading cause of cancer death in females,
even if in some countries, such as Asia, the absolute number
of cervical cancer cases has decreased from 4,443 in 1999 to
3,857 in 2010 [1,2].  
It is well established that concurrent chemoradiation
(CRT), as well as neoadjuvant chemotherapy (NACT) fol-
lowed by radical surgery (RS), are both superior to radiother-
apy alone in terms of overall survival (OS), in locally 
advanced cervical cancer (LACC) management [3,4]. But sev-
eral controversies still exist to identify the more appropriate
strategy. Tumor down staging, improved resectability and
potential beneficial effects on micrometastasis encourage the
use of a NACT approach in the management of this disease
[5]. In the era of individualized cancer treatment, the use of
prediction model to estimate survival outcomes would be
particularly helpful in clinical decision-making. Different
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prognostic models are available in LACC patients receiving
CRT [6-10]. Whereas, a prognostic predictor for LACC 
patients treated with NACT plus RS has not yet been imple-
mented and validated.
The aim of the current study was to find clinicopathologic
variables associated with OS and progression-free survival
(PFS) following curative NACT and RS for LACC, and create
a nomogram for individual risk prediction. 
Materials and Methods
1. Study population
Clinical data of cervical cancer patients undergoing NACT
and surgical curative resection between January 2004 and
December 2011 were retrospectively collected from our
dataset. Patients with distant metastases at diagnosis, unop-
erated, with history of previous pelvic radiation therapy or
chemotherapy and those with missing data were excluded.
All patients were treated with a multimodal treatment 
approach, including platinum-based chemotherapy and sur-
gery, scheduled 5-7 weeks after the end of NACT, independ-
ently of clinical response. The NACT regimen was not
predetermined, but minimal requirements were a cisplatin-
containing regimen with a 225 mg/m2 total cisplatin dose
with a maximum of two additional drugs, administered over
a period of 6 to 8 weeks.
Before NACT, all patients were submitted to a gynecolog-
ical examination under general anesthesia. A total body com-
puted tomography (CT) scan or magnetic resonance imaging
(MRI) was performed in all patients. Cystoscopy was per-
formed in patients with suspected advanced disease in the
anterior parametria at gynecological examination or having
a suspicious invasion on CT scan or MRI. After three cycles
of NACT, patients were clinically reassessed and classified
as suitable or unsuitable for RS. RS consisted of systematic
(at least 20 nodes to be resected) pelvic lymphadenectomy
plus radical hysterectomy (type III to V) plus. Aortic lym-
phadenectomy was reserved for patients with pelvic node
disease at intraoperative examination or finding of bulky aor-
tic nodes at preoperative imaging or at time of surgery. If 
required, additional surgical procedures were performed:
ureteral, full thickness and extramucosal bladder resection,
uretero-ureteral anastomosis, or ureteral reimplantation. 
Patients not considered amenable of radical surgery after
chemotherapy treatment were excluded from our analysis
(intention per protocol analysis) as well as patients whose
physical condition made optimal surgery unsafe (Eastern 
Cooperative Oncology Group performance status 2 after
NACT; serious comorbidities).  Patients deemed inoperable
were offered chemoradiotherapy or palliative chemotherapy. 
After radical surgery, all specimens were histopathologi-
cally reviewed, and the pathological TNM class and stage
were determined according to the classification established
by the American Joint Committee on Cancer, seventh edition
[11]. Patients staged with a prior edition staging system were
restaged according to the seventh edition. According to 
institutional policy, adjuvant treatment, such as chemother-
apy and/or radiotherapy, was recommended in those 
patients with pathologic risk factors detected in the operative
specimen, including positive vaginal margin, positive para-
metrial margin, and pelvic or aortic lymph node metastasis.
Adjuvant radiotherapy was used to treat the whole pelvis,
including the common iliac and periaortic lymph nodes if
positive. Patients were followed according to internal proto-
col weekly during chemotherapy treatment and up to 2
weeks postsurgery. After treatment, patients were monitored
3 monthly intervals for the first 2 years, at 4-6 monthly inter-
vals for the additional 2 years, and annually for subsequent
years. Patients were followed up closely to detect persistent
or recurrent disease by clinical examination. Imaging,
positron emission tomography/CT or CT scan, was per-
formed 12 weeks after surgery to assess disease response. We
included only patients for whom at least 5-year follow-up
was available, because OS nomogram reflect 5-year event
rates.
2. Statistical analysis
Statistical analysis was carried out using R-Studio 0.98.
1091 software and SPSS ver. 24.0 (IBM Corp., Armonk, NY).
Standard descriptive statistics were used to evaluate the dis-
tribution of each factor. Continuous variables were presented
as medians and ranges, and dichotomous variables were pre-
sented as percentages. Student’s t test and Wilcoxon rank-
sum test were used to evaluate any differences in continuous
variables; Pearson’s chi-square test or Fisher exact test was
used for categorical variables. 
OS and PFS were calculated in months from the date of 
diagnosis to the first event, including date of the last follow-
up or death (OS) and/or relapse (PFS).
The evaluated variables were age (< 50 vs.  50), smoker
(no vs. yes), body mass index (BMI; < 25 vs.  25), tumor size
(< 4 cm vs.  4 cm), tumor histology (squamous cell carci-
noma vs. other histologies), tumor grade (G1 vs. G2 vs. G3),
International Federation of Gynecology and Obstetrics
(FIGO) disease stage (IB2-IIA vs. IIB vs. III), lymphovascular
space invasion (absence vs. presence), positive parametria
(no vs. yes), and pathologic nodal status (negative vs. posi-
tive). Firstly, univariate analysis was carried out to assess the
single variables for predictive power. Then, those variables
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associated with a p-value of  0.25 were included in a multi-
variate survival Cox regression analysis. All reported p-val-
ues are two-sided, and p-values lower than 0.05 were
considered significant. 
Independently of statistical significance, we decided to 
include variables as nomogram parameters because non-sig-
nificant variables should be assumed to have a minimal effect
on survival. Nomograms were constructed to visualize the
effect of each selected variable on the estimated probability.
Internal validation was performed using the bootstrap
method to estimate the optimism of the model. We perform
bootstrap validation using 200 bootstrap datasets con-
structed by sampling with replacement from the original
data but in such a way to maintain the same ratio of long
term survivors relative to the number of patients surviving
for less than 2 years (PFS) and 5 years (OS) [12]. 
3. Ethical statement
The data were analyzed retrospectively from a database
compiled prospectively, this procedure does not require the
approvation by the Institutional Review Board but only the
approval of the department that was obtained.
Patients have signed a consensus regarding the use of their
data for scientific research.
Table 1. Patient characteristics
Characteristic No. (%)  
Age (yr)
Median (range) 51 (24-83)
< 50 116 (47.3)
 50 129 (52.7)
Smoker
Yes 56 (22.9)
No 189 (77.1)
Body mass index (kg/m2)
< 25 165 (67.3)
 25 80 (32.7)
Histology
Squamous 208 (84.9)
Adenocarcinoma 27 (11)
Adenosquamous 10 (4.1)
Tumor size (cm)
< 4 181 (73.9)
 4 64 (26.1)
Grading
1 16 (6.5)
2 126 (51.4)
3 103 (42.1)
FIGO stage
IB2 40 (16.4)
IIA 21 (8.6)
IIB 115 (46.9)
IIIA 9 (3.7)
IIIB 60 (24.4)
Table 2. Histopathological characteristics 
Characteristic No. (%)  
Lymph vascular space invasion
Yes 44 (18)
No 201 (82)
Parametria invasion
Yes 70 (25.3)
No 175 (71.4)
Lymph node involvment
Yes 63 (25.9)
No 182 (74.1)
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Fig. 1.  Overall survival according to International Feder-
ation of Gynecology and Obstetrics stage.
FIGO, International Federation of Gynecology and Obstet-
rics.
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Results
A total of 245 patients who underwent neoadjuvant plat-
inum-based chemotherapy and radical surgery for primary
cervical carcinoma were included in the study. The general
characteristics of the patients are listed in Table 1. Mean age
at diagnosis was 51 years and the vast majority of patients
(n=184, 75.1%) had at least tumor with parametrial invasion.
Histo-pathological details are shown in Table 2.
1. Overall survival
The median OS was 144 months with a 5-year OS of 72.6%
(95% confidence interval [CI], 0.66 to 0.79). Overall, FIGO dis-
ease stage was strongly associated with OS with a 5-year OS
rates of 90.8% (95% CI, 0.79 to 0.96), 72.6% (95% CI, 0.61 to
0.81), and 52.5% (95% CI, 0.37 to 0.66), for FIGO stage IB2-
IIA, IIB, and III, respectively (p < 0.001) (Fig. 1). On univari-
ate analysis, smoke, tumor size, FIGO disease stage, lympho-
vascular space invasion, positive parametria, and positive
lymph-nodes were significant prognostic factors associated
with OS (Table 3). On multivariate analysis, tumor size, grad-
ing, and parametria status were independently prognostic
(Table 2).  
2. Progression-free survival
Median time for PFS was 98 months (range, 84 to 140
months). The 2-year and 5-year PFS were 83.7% and 66%, 
respectively (Fig. 2). On univariate analysis, tumor size,
FIGO stage, lymphovascular space invasion, parametria sta-
tus and positive lymph-nodes were predictive for PFS. Age,
tumor size, and positive parametria affected the rate of PFS,
in multivariate analysis. Details are shown in Table 4. 
3. Nomograms
To account for the importance of tumor and clinical patho-
logical factors, the most predictive variables were used to cre-
ate two nomograms, one to predict the 5-year probability of
OS and the other to predict the 2-year probability of PFS. The
concordance index of the OS nomogram was 0.66, whereas
the concordance index of the PFS nomogram was 0.64. Cali-
bration plots demonstrated good agreement between pre-
Variable
Univariate analysis Multivariate analysis
Hazard ratio p-value Hazard ratio p-value
Age (< 50 yr vs.  50 yr) 0.90 (0.56-1.45) 0.68 - -
Smoker (no vs. yes) 3.05 (1.22-7.60) 0.02 2.34 (0.86-6.38) 0.10
BMI (< 25 kg/m2 vs.  25 kg/m2) 0.88 (0.53-1.44) 0.62 - -
Histology (squamous vs. other) 0.58 (0.76-3.32) 0.21 1.16 (0.47-2.88) 0.74
Tumor size (< 4 cm vs.  4 cm) 0.38 (0.20-0.71) < 0.01 0.49 (0.24-1.02) 0.05
Grading (1-2 vs. 3) 0.63 (0.39-1.01) 0.06 0.48 (0.27-0.86) 0.01
FIGO stage (IB-II vs. III) 0.43 (0.26-0.70) < 0.01 0.69 (0.37-1.30) 0.25
LVSI (no vs. yes) 0.32 (0.19-0.53) < 0.01 0.86 (0.43-1.71) 0.67
Positive parametria (no vs. yes) 0.21 (0.13-0.35) < 0.01 0.43 (0.19-0.97) 0.04
Positive lymph nodes (no vs. yes) 0.26 (0.16-0.42) < 0.01 0.54 (0.23-1.24) 0.14
Table 3. Overall survival univariate and multivariate analysis
BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion.
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Fig. 2.  Disease-free survival for the entire study popula-
tion.
Claudia Marchetti, Survival Nomograms in Cervical Cancer after NACT
VOLUME 50 NUMBER 3 JULY 2018  771
dicted and actual probability of OS and PFS, respectively.
Fig. 3 can be used to compute the probability of 5-year OS
and Fig. 4 to calculate the probability of 2-year PFS. The sum
of each variable point was plotted on the total point axis, and
the estimated median 5-year OS and 2-year PFS rates were
respectively obtained by drawing a vertical line from the
plotted total point axis straight down to the outcome axis. 
To demonstrate nomograms applicability, we introduced
a representative clinical case. Inside parenthesis, it is 
reported for each factor its OS point/PFS point, respectively.
A 75-year-old woman (0 point/0 point) with clinical FIGO
IIB (20 points/5 points) squamous cell (0 point/0 point) G3
(37 points/32.5 points) cervical cancer was treated at our 
department. Her pretreatment BMI was 22.2 (63 points/48
points). She had a primary tumor size of 4.5 cm (57 points/
47.5 points). She underwent NACT plus RS, without lym-
phovascular space invasion invasion (0 point/0 point), para-
metria invasion (0 point/0 point), and lymph node invo-
lvement (0 point/0 point). The nomograms predict a 5-year
OS of 85% and a 2-year PFS of 98%. After a follow-up of 25
months, the patient is still alive, without any evidence of dis-
ease.
Discussion
The present study suggests that grading, tumor size at 
diagnosis, and parametrial involvement are independent
prognostic factors of OS in LACC. These variables with the
exception of tumor grade were predictive for PFS. Further-
more, we were able to develop a robust nomogram that can
provide individual estimations of treatment outcome in this
patient population.
NACT followed by radical hysterectomy is a valid alterna-
tive to concurrent CRT for patients with stage IB2-III cervical
cancer; furthermore, in both randomized control trials and
meta-analysis, it has been shown to be superior to radiother-
apy alone and to prevent radiotherapy-related side effects
[4,5].
With this regard, we have previously demonstrated [13] in
a relatively large population that several pathological (grad-
ing, histotype) and clinical features (FIGO stage, tumour size
> 5 cm, and parametrical involvement) strongly correlate
with survival in patients submitted to this approach. To our
knowledge, our nomograms represent the first attempt to 
develop a multifactorial prognostic model in LACC receiving
NACT plus RS. First of all, it should be noticed that survival
data of our series compares well with other previously pub-
lished in a similar setting of women affected by LACC who
received CRT instead of NACT plus RS. In fact, we obtained
a 5-year OS rates of 90.8%, 72.6%, and 52.5% for FIGO stage
IB2-IIA, IIB, and III, respectively, which is similar [14] other-
wise higher [15] than those recently reported, suggesting that
NACT followed by RS is a feasible and effective treatment
option in LACC and deserves to be further discussed and 
investigated.
Our analysis also demonstrates that the degree of tumor
extent is highly predictive of OS and PFS. This is in accor-
dance with our previous data [13]. As all patients received
NACT, it is easy to interpret these data as the logical conse-
quence of the correlations between the disease volume and
the tumor cell kinetics. The greater the volume, the larger the
hypoxic and resting phase cell population with reduced or
no chemosensitivity and the probability of developing resist-
ant clones. 
Accordingly with previous findings [15,16], we have also
Variable
Univariate analysis Multivariate analysis
Hazard ratio p-value Hazard ratio p-value
Age (< 50 yr vs.  50 yr) 0.72 (0.48-1.09) 0.13 0.60 (0.37-1.00) 0.05
Smoker (no vs. yes) 0.72 (0.40-1.27) 0.26 - -
BMI (< 25 kg/m2 vs.  25 kg/m2) 0.98 (0.63-1.50) 0.93 - -
Histology (squamous vs. other) 1.19 (0.67-2.10) 0.54 - -
Tumor size (< 4 cm vs.  4 cm) 0.41 (0.24-0.70) < 0.01 0.54 (0.30-0.97) 0.04
Grading (1-2 vs. 3) 0.33 (0.10-1.06) 0.07 0.70 (0.43-1.15) 0.16
FIGO stage (IB-II vs. III) 0.35 (0.23-0.52) < 0.01 0.65 (0.39-1.09) 0.10
LVSI (no vs. yes) 0.30 (0.20-0.47) < 0.01 0.63 (0.34-1.15) 0.13
Positive parametria (no vs. yes) 0.28 (0.18-0.42) < 0.01 0.44 (0.22-0.86) 0.02
Positive lymph nodes (no vs. yes) 0.34 (0.22-0.51) < 0.01 0.74 (0.36-1.54) 0.42
Table 4. Disease-free survival univariate and multivariate analysis
BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion.
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found that parametrial involvement is a prognostic factor of
both OS and PFS; besides, it appears to be predominating in
the multifactorial model. Differently from other nomogram
in LACC in which parametrial involvement was defined only
on the basis of radiological findings [14], it should be under-
lined that one of the peculiarity of our study is that we only
considered patients who had received RS and therefore our
characterization of parametrial involvement is exclusively
pathology-proven, suggesting a higher accuracy. 
Regarding lymph nodal involvement, several reports
found it to be an important prognostic factor [15,16]. In our
multivariate analysis we did not confirm this finding, albeit
the effect of lymph node involvement was substantial in our
multifatcorial model. As stated before, it should be high-
lighted that all of our patients underwent pelvic with or
without paraortic lymphadenectomy. This surgical approach
is in contrast with nomograms developed with other cohort
of patients, in which less than 37% patients underwent 
laparoscopic sampling of pelvic/paraaortic lymph nodes and
therefore, lymph nodal status was defined on the basis of a
non-homogeneous radiological evaluation [14]. 
Controversial data have been proposed regarding the 
impact of younger age on prognosis and some authors sug-
gested that younger age is a predictor of unfavourable prog-
nosis, particularly in more advanced stages [17]. This was
supported on the assumption that if the risk of progression
Fig. 3. Five-year overall survival nomogram. BMI_25 indicates body mass index  25 (1) or < 25 (0). Age_50 indicates age 
 50 (1) or < 50 (0) at diagnosis. Tsize_4 indicates clinical tumor size  4 (1) or < 4 (0). Squamous indicates squamous cell car-
cinoma (1) or other tumor histologies (2). LVSI indicates presence (1) or absence (0) of lymphovascular space invasion. Pos-
itive_lymph_nodes indicates pathological positive (1) or negative (0) locoregional lymph nodes. Positive_parametria indicates
pathological positive (1) or negative (0) parametria. To use, find patient’s BMI on BMI_25 axis, then draw straight line upward
to points axis to determine how many points patient receives for BMI. Do this again for other axes, each time drawing straight
line upward toward points axis. Sum points received for each variable, and find sum on total points axis. Draw straight line
down to survival-probability axis to find patient’s probability of 5-year OS. BMI, body mass index; FIGO, International Fed-
eration of Gynecology and Obstetrics; OS, overall survival.
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from mild dysplastic changes of the cervix to severe dyspla-
sia, let alone cancer, is only 1% per year, then the develop-
ment of cancer in young women, especially the very young,
must be more aggressive. In our cohort of patients, we found
a slightly significant trend of younger age to be associated
with disease-free survival (DFS). Therefore, we included age
into our model. Nonetheless, the role of age on survival still
needs to be more deeply clarified; differently, the correlation
between age and response to chemotherapy seems to be
stronger, suggesting that younger patients might achieve a
higher response to NACT; this will be refined in further 
research planned in this study population (analysis ongoing,
data not shown).
One limitation of our nomograms is that they are based
solely on disease outcomes and do not account for the risk
of treatment-related toxicity. Moreover, we are still in process
to validate these nomograms on other cohort of patients to
ensure their generalizability, thus at present they should be
considered hypothesis generating rather than confirmatory.
Developing a nomogram for prognosis or treatment pre-
diction has been considered helpful in individualized medi-
cine and successful applications have been utilized in many
malignancies [18-21]. This statistically based tool provides a
predicted probability of a specific outcome, using a com-
bined set of proven or potential prognostic factors. Another
possible application of the nomograms could be the oppor-
Fig. 4. Two-year progression-free survival  nomogram. BMI_25 indicates body mass index  25 (1) or < 25 (0). Age_50 indi-
cates age  50 (1) or < 50 (0) at diagnosis. Tsize_4 indicates clinical tumor size  4 (1) or < 4 (0). Squamous indicates squamous
cell carcinoma (1) or other tumor histologies (2). LVSI indicates presence (1) or absence (0) of lymphovascular space invasion.
Positive_lymph_nodes indicates pathological positive (1) or negative (0) locoregional lymph nodes. Positive_parametria 
indicates pathological positive (1) or negative (0) parametria. To use, find patient’s BMI on BMI_25 axis, then draw straight
line upward to points axis to determine how many points patient receives for BMI. Do this again for other axes, each time
drawing straight line upward toward points axis. Sum points received for each variable, and find sum on total points axis.
Draw straight line down to survival-probability axis to find patient’s probability of 2-year PFS. BMI, body mass index; FIGO,
International Federation of Gynecology and Obstetrics; PFS, progression-free survival.
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tunity to tailor follow-up schedules. Apart from early man-
agement of complications, documentation of outcomes and
maintaining the patient–physician relationship, the main aim
of clinical follow-up is improvement of survival. While it
seems obvious that intensive follow-up improves patient
outcome, there is debate about the intensity. The nomograms
could assist in creating an individual follow-up schedule.
Our nomograms can assist in the decision when to treat a
LACC patient treated with NACT plus RS, based on the 
individual risk for progression disease and death. 
In summary, we constructed a nomogram based on clini-
cal-pathological features in order to predict 2-year PFS and
5-year OS in locally advanced cervical cancer primarily
treated with NACT followed by RS. This tool might be par-
ticularly helpful for assisting in the follow up of cervical can-
cer patients who have not undergone concurrent chemora-
diotherapy. Our model indicates that parametrial involve-
ment seems to be a major prognostic factor of both OS and
DFS; besides, it appears to be predominating in the multifac-
torial model and thus should be systematically assessed by
pathologists to help with prognostication. 
To help guide decision-making, we have developed a clin-
ically useful tool to predict the probability of both OS and
PFS in LACC patients treated by NACT and RS.
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